Ann D Thor
Overview
Explore the profile of Ann D Thor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
2539
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wahdan-Alaswad R, Edgerton S, Kim H, Tan A, Haugen B, Liu B, et al.
Cell Cycle
. 2023 Sep;
:1-20.
PMID: 37723865
Estrogen receptor (ER) α expression and associated signaling is a major driver of over two-thirds of all breast cancers (BC). ER targeting strategies are typically used as a first-line therapy...
2.
Lyu H, Shen F, Ruan S, Tan C, Zhou J, Thor A, et al.
Cancer Cell Int
. 2023 Sep;
23(1):204.
PMID: 37716943
Background: Triple negative breast cancer (TNBC) represents a significant clinical challenge. Chemotherapy remains the mainstay for a large part of TNBC patients, whereas drug resistance and tumor recurrence frequently occur....
3.
Wellberg E, Corleto K, Checkley L, Jindal S, Johnson G, Higgins J, et al.
Breast Cancer Res
. 2022 Jun;
24(1):42.
PMID: 35725493
Background: Obesity and adult weight gain are linked to increased breast cancer risk and poorer clinical outcomes in postmenopausal women, particularly for hormone-dependent tumors. Menopause is a time when significant...
4.
Wahdan-Alaswad R, Liu B, Thor A
Cancer Drug Resist
. 2022 May;
3(2):179-198.
PMID: 35582612
Approximately 20% of invasive breast cancers have upregulation/gene amplification of the oncogene human epidermal growth factor receptor-2 (HER2/ErbB2). Of these, some also express steroid receptors (the so-called Luminal B subtype),...
5.
Liu S, Polsdofer E, Zhou L, Ruan S, Lyu H, Hou D, et al.
Mol Ther Oncolytics
. 2021 Jun;
21:303-314.
PMID: 34141868
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows promising antitumor activity in preclinical studies. However, the efficacy of recombinant TRAIL in clinical trials is compromised by its short serum half-life and...
6.
Wahdan-Alaswad R, Edgerton S, Salem H, Kim H, Tan A, Finlay-Schultz J, et al.
Clin Cancer Res
. 2020 Oct;
27(2):585-597.
PMID: 33097494
Purpose: Thyroid disease is a frequent comorbidity in women with breast cancer, and many require thyroid hormone replacement therapy (THRT). We postulated that THRT has a deleterious clinical effect mechanistically...
7.
Canfield G, Reingold S, Ho A, Thor A, Pecen P, Desanto K, et al.
IDCases
. 2020 Sep;
22:e00931.
PMID: 32884904
We describe a case of Cryptococcal choroiditis in a person with advanced HIV/AIDS. A 29-year-old male with AIDS presented with fever, photophobia, and ataxia secondary to cryptococcal and toxoplasma meningoencephalitis....
8.
Wellberg E, Kabos P, Gillen A, Jacobsen B, Brechbuhl H, Johnson S, et al.
JCI Insight
. 2018 Jul;
3(14).
PMID: 30046001
Obesity increases breast cancer mortality by promoting resistance to therapy. Here, we identified regulatory pathways in estrogen receptor-positive (ER-positive) tumors that were shared between patients with obesity and those with...
9.
Giles E, Jindal S, Wellberg E, Schedin T, Anderson S, Thor A, et al.
Breast Cancer Res
. 2018 Jun;
20(1):50.
PMID: 29898754
Background: Obesity and type II diabetes are linked to increased breast cancer risk in postmenopausal women. Patients treated with the antidiabetic drug metformin for diabetes or metabolic syndrome have reduced...
10.
Lee H, Saini N, Howard E, Parris A, Ma Z, Zhao Q, et al.
Sci Rep
. 2018 May;
8(1):6829.
PMID: 29717218
Although ErbB2-targeted therapeutics have significantly improved ErbB2 breast cancer patient outcomes, therapeutic resistance remains a significant challenge. Therefore, the development of novel ErbB2-targeting strategies is necessary. Importantly, ErbB2 is a...